Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pembrolizumab
pembrolizumab+ epacadostat · 1 trial · 1 indication
Progression-free survival, defined as the time from date of randomization until the earliest date of disease progression, as determined by independent central review of objective radiographic disease assessments per RECIST 1.1, or death from any cause, whichever comes first.
Defined as time from date of randomization to date of death due to any cause. OS was calculated using product-limit (Kaplan-Meier) method for censored data.
| Arm | Type | Description |
|---|---|---|
| Pembrolizumab + Epacadostat | EXPERIMENTAL | Pembrolizumab + Epacadostat |
| Pembrolizumab + Placebo | ACTIVE_COMPARATOR | Pembrolizumab + Placebo |
| Name | Type | Description |
|---|---|---|
| pembrolizumab + epacadostat | DRUG | * Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Epacadostat will be administered orally daily starting at Day 1 (Week 1) |
| pembrolizumab + placebo | DRUG | * Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Placebo will be administered orally daily starting at Day 1 (Week 1) |
Inclusion Criteria: * Have histologically or cytologically confirmed melanoma * Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy * A minimum of 1 measurable lesion by CT or MRI * Provide a baseline tumor biopsy * Eastern Cooperative Oncology...
Top 20 of 51 competitors
MK-3475, also known as pembrolizumab, is an investigational antibody being studied in oncology. It is being evaluated in clinical trials for head and neck cancer, melanoma, colorectal cancer, lung cancer, urothelial cancer, and triple-negative breast cancer. It is currently in Phase 1 development.
MK-3475 is a monoclonal antibody, a type of -mab antibody. It is being studied in combination with other agents in clinical trials for various cancers, including melanoma and renal cell carcinoma. Its specific molecular target is not disclosed in the available information.
MK-3475 is being developed by Incyte Corporation, which is listed on the stock exchange under the ticker INCY. The drug is currently in Phase 1 clinical development for multiple oncology indications.
MK-3475 is in Phase 1 of clinical development. It is an investigational drug and has not been approved by regulatory authorities. It is being studied in clinical trials for several cancer types, including melanoma and triple-negative breast cancer.
MK-3475 is being studied in several clinical trials. These include a Phase 3 trial in melanoma (NCT02752074), a Phase 3 trial in renal cell carcinoma (NCT03260894), and Phase 2 trials in triple-negative breast cancer (NCT05491226 and NCT07015853). The trials are conducted in multiple countries.
Yes, MK-3475 is also known as pembrolizumab. The drug is being studied under both names in clinical trials. It is an investigational antibody being developed by Incyte Corporation for various cancer indications.